February 20, 2026
On September 9, 2025, the U.S. Food and Drug Administration published a high‑profile press announcement describing a major enforcement push on deceptive drug advertising and confirmed it was sending thousands of letters across the industry, plus approximately 100 cease‑and‑desist letters tied to allegedly deceptive ads. FDA linked the initiative to concerns about consumers not receiving a fair balance of benefits and risks, and specifically called out the way digital and social media (including undisclosed influencer promotion) can blur editorial content and advertising.
Even if your company sells CBD or THC beverages rather than FDA‑approved prescription drugs, this September 2025 action is a clear signal that federal regulators are:
For CBD and THC‑drink brands operating in a fragmented national market, the practical takeaway is simple: the era of “wellness‑style” claim creativity with thin evidence is ending. Marketers should behave as if they are already in the higher‑scrutiny world the FDA is openly building.
External references:
The September 2025 materials weren’t written for cannabinoid beverages, but the enforcement themes map directly onto the most common regulatory failure modes in cannabinoid drink advertising.
In prescription drug advertising, fair balance is a long‑standing concept: benefits can’t be presented in a way that minimizes or obscures risks. FDA’s September 2025 communications emphasized that many ads create misleading impressions by what they omit—especially when consumers encounter benefit-heavy messages in short‑form video, paid social, and influencer content.
For CBD/THC beverages, the legal framework is different, but the consumer‑protection logic is the same and increasingly shared across agencies:
If your ad communicates “this will change how you feel/perform” but hides key limitations (dose variability, delayed onset, impairment risk, interaction risk, etc.), you are functionally creating the same problem FDA is trying to eliminate in drug ads.
FDA’s September 2025 letter to industry explicitly pointed to the modern reality that consumers encounter marketing in feeds, stories, short videos, and creator content—often without context.
For cannabinoid beverages, “disclosures must travel with the claim” means:
A helpful parallel is FDA’s thinking about character-limited platforms for regulated products: if you cannot include truthful, non‑misleading context in the space, don’t run the claim in that format.
Reference (FDA draft guidance on character space limitations, relevant as an enforcement mindset even outside Rx): https://www.fda.gov/media/88551/download
FDA’s September 2025 letter flagged undisclosed influencer promotion as part of the problem in modern advertising ecosystems. FTC has already built the enforcement framework for this: the Endorsement Guides were updated in 2023 and emphasize that disclosures must be clear and conspicuous, that built‑in platform tools may be insufficient, and that advertisers can be liable for misleading or unsubstantiated statements communicated through endorsements.
Key FTC reference:
CBD and THC‑drink marketing sits in a high‑risk overlap of:
FDA continues to state that, aside from certain hemp seed ingredients, cannabis-derived ingredients have not been approved for use in food via a food additive petition or evaluated GRAS notification, and that FDA has not approved CBD for use in food.
Reference:
This matters for marketers because, in a contested regulatory environment, promotional content becomes more important evidence. If you market a beverage as having disease‑related benefits or as a “treatment,” you increase the chance regulators view it as an unapproved drug rather than a conventional food.
In July 2024, the FTC and FDA publicly announced a second set of cease‑and‑desist letters to companies selling delta‑8 THC products in packaging designed to look like children’s snacks, urging the companies to immediately stop marketing practices likely to appeal to young children.
Reference:
Even if your brand is not in that category, the broader lesson applies: creative direction is now a compliance issue. Flavor names, cartoon‑adjacent design language, candy cues, and youth-coded influencer style can become evidence of irresponsible marketing.
Regulators don’t just look for explicit disease claims. They also challenge implied messages and unsupported performance promises. Based on FDA/FTC patterns and the September 2025 crackdown themes, the following claim clusters deserve immediate attention.
“Fast‑acting,” “works in 10 minutes,” or “hits quickly” claims create two problems:
If you want to communicate onset expectations, the lower‑risk route is to:
“Microdosed” and “precision dosing” claims can be interpreted as:
If you make precision claims, your substantiation file should typically include:
Phrases like “relieves anxiety,” “treats insomnia,” “reduces inflammation,” “pain relief,” “hangover cure,” or “ADHD support” are routinely treated as drug claims when tied to a product.
Even softer language—“calms panic,” “stops racing thoughts,” “replaces my meds,” “clinically proven for stress”—can create the same intended‑use problem.
For consumer advertising risk, remember FTC’s standard: health benefit claims must be supported by competent and reliable scientific evidence, and for many meaningful health outcomes, FTC expects high‑quality human evidence (often randomized controlled trials depending on the claim).
Reference:
If your product contains THC (including hemp-derived THC variants), “non‑intoxicating” claims are inherently risky because they promise an experiential outcome that is:
If you communicate “no high,” you should be prepared to substantiate what that means and to define conditions of use. In many cases, a safer approach is to avoid absolute language and instead provide responsible-use guidance.
In 2026, it’s no longer enough to say “we have studies” or “the ingredient is known for this.” Brands should maintain a structured claim substantiation system that can survive an FDA/FTC inquiry, a state AG CID, or a competitor challenge.
A practical “audit-ready” substantiation file for each claim should include:
This governance work is not busywork. FDA’s September 2025 initiative explicitly framed enforcement as a response to widespread violations and confusion in modern advertising channels. A well-kept substantiation file is one of the few things that shortens enforcement response time and can reduce escalation risk.
A recurring failure pattern in regulated wellness categories is inconsistency:
That inconsistency is a problem because regulators evaluate the total promotional ecosystem.
For CBD/THC beverages, harmonization generally means:
FTC has repeatedly warned that marketers can be responsible for claims communicated through testimonials and endorsements. If your brand reposts a user video saying “this fixed my anxiety” or “this cured my insomnia,” you may have adopted that claim.
Under the 2023 Endorsement Guides updates, the FTC also flagged manipulation or distortion of reviews as a problem area. If you curate reviews, document your policy.
Reference:
Because of the joint FDA/FTC focus on youth-appealing edible product presentation in recent years, beverage marketers should treat “kid appeal” as a red line.
Remove or redesign:
This is not only a federal risk; it invites state-level action and retailer deplatforming.
Many beverage brands use subscriptions (monthly drops, bundles, autoship). The FTC finalized an amended Negative Option Rule (“click-to-cancel”) in 2024 and later delayed enforcement, but the legal risk around subscriptions did not disappear.
Even where the rule’s status is in flux due to litigation, brands still face enforcement risk under:
Practical compliance steps that align with FTC expectations:
FTC reference (business blog explaining the amended rule): https://www.ftc.gov/business-guidance/blog/2024/10/click-cancel-ftcs-amended-negative-option-rule-what-it-means-your-business
If September 2025 taught the market anything, it’s that regulators see influencers as a central distribution channel, not an edge case.
A scalable influencer compliance wrapper should include:
If you allow affiliates to create their own copy, you must treat that as a controlled compliance surface area—not “their problem.”
FDA’s September 2025 initiative indicates an enforcement culture that expects companies to be able to show their work. Here is a practical 30‑day plan.
Include:
Flag and triage:
For every claim you keep, ensure you have competent and reliable scientific evidence that matches the exact message consumers take away.
Use the FTC Health Products Compliance Guidance as your internal benchmark for evidence quality and claim mapping.
Operationally, this means:
If FDA/FTC or a state AG contacts you, your ability to produce this record quickly can materially affect the trajectory of the inquiry.
Train customer support to avoid:
Document training and keep canned responses consistent with your claims policy.
This article is for informational purposes only and does not constitute legal advice. Federal and state requirements can change quickly, and the compliance analysis for any specific product depends on facts, jurisdiction, and marketing context.
If you’re updating creative, rebuilding substantiation files, or tightening influencer/subscription governance, CannabisRegulations.ai can help your team turn principles into repeatable workflows—so you can scale marketing while reducing regulatory risk.
Visit https://www.cannabisregulations.ai/ to explore compliance tools, regulatory insights, and practical playbooks for licensing and advertising-ready operations.
